For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments.
The New Jersey- and Israel-based company has emerged as a biotech underdog with strong tailwinds that analysts at HC Wainwright and Zacks Small Cap Research believe puts it the brink of sustainable profitability.
The bullish outlook follows revenue growth from its flagship drug, Elfabrio, a treatment for Fabry disease in adult patients, a rare genetic disorder caused by a deficiency in the enzyme alpha-galactosidase A, which leads to the buildup of harmful fat deposits in the kidneys, heart, and nervous system. Without treatment, Fabry disease can cause severe organ damage and life-threatening complications.
Addressing rare diseases
Elfabrio, a PEGylated enzyme replacement therapy, is gaining traction globally under commercialization partner Chiesi Global Rare Diseases.
“Protalix may achieve sustainable profitability from this year forward, driven mainly by the Elfabrio royalty stream,” HC Wainwright analysts wrote in a recent note.
CEO Dror Bashan
Elfabrio’s competitive advantages over existing treatments like Fabrazyme and Replagal include longer presence in the bloodstream and reduced immune response.
Beyond Fabry disease, Protalix has an established presence in treating Gaucher disease, another rare genetic disorder caused by a deficiency in the enzyme glucocerebrosidase, leading to an accumulation of fatty substances in the spleen, liver, and bone marrow. The company’s Gaucher treatment, Elelyso, is marketed globally through a long-standing partnership with Pfizer and maintains a 25% market share in Brazil. Unlike Elfabrio, where Protalix collects royalties, the company directly benefits from Elelyso sales in Brazil.
A biotech company built on a unique platform
At the core of Protalix’s success is ProCellEx, its proprietary plant cell-based expression system for producing biologic drugs expressing complex human proteins through plant cells in suspension. Unlike traditional mammalian cell-based production, which dominates the biotech industry, ProCellEx offers a more simplified process to manufacture complex human proteins.
“As far as we know, ProCellEx is the only system capable of expressing complex human proteins through plant cells in suspension,” CEO Dror Bashan said in an interview with Proactive.
The first company to receive FDA approval for a protein produced through a plant cell-based expression system, Protalix now has two FDA-approved drugs developed using ProCellEx. The platform’s advantages include a simplified manufacturing process, natural viral resistance, and flexible scalability.
Bashan noted that Protalix is exploring ways to expand ProCellEx’s capabilities, potentially opening the door to new therapeutic areas. “If this works, it could open up exciting new possibilities,” he said. “It’s a dream, but certainly not a fantasy.”
Pipeline expansion drives future growth
While Elfabrio remains the centerpiece of Protalix’s commercial success, the company is advancing PRX-115, a recombinant PEGylated uricase designed to treat uncontrolled gout. HC Wainwright called it a “risk-mitigated, possibly underrated future contributor”, with promising Phase 1 results showing dose-dependent reductions in plasma uric acid levels lasting up to 12 weeks. A Phase 2 trial is expected in the second half of 2025.
CFO Eyal Rubin
Meanwhile, Protalix’s financial position has dramatically improved. The company eliminated $65 million in debt over the last five years and held as of September 30, 2024, over $27 million in cash, making it one of the few small-cap biotech firms that is both revenue- and cash-generating.
“We paid off our debt primarily through revenue from sales and an equity offering executed in 2021 while maintaining a disciplined approach to dilution,” CFO Eyal Rubin said. “Now the company is in a very nice spot. Only a few small-mid cap companies are revenue and cash generating with sufficient means to support existing plans.”
With a growing royalty stream from Elfabrio, stable revenue from Elelyso, and a promising drug pipeline, analysts believe Protalix’s upside could be substantial.
“If Phase 2 results for PRX-115 mirror those of Phase 1, we could have a highly valuable asset,” Bashan said. “Overall, there is a strong probability that we will grow the company significantly, with potential upsides that could even exponentially increase its value.”
The company is also exploring early-stage research into rare renal diseases and additional lysosomal disorders. "Our approach is to target therapies that address real unmet medical needs," Bashan said. "While it’s an innovative and complex process that will take time, it holds great potential."
Is Protalix a buy?
With a robust revenue stream from Elfabrio, a promising pipeline, and a strong financial foundation, Protalix appears well-positioned for future growth. Analyst targets suggest significant upside from current levels, but as with any biotech investment, risks remain. Clinical setbacks or regulatory delays could impact the company’s trajectory.
That said, Protalix has proven its ability to develop and commercialize rare disease treatments, a feat that few small-cap biotechs achieve. As the company moves forward with its next phase of growth, investors will be watching closely to see if Protalix can turn its potential into lasting shareholder value.
"We have a strong R&D team that has already brought two drugs to market," Bashan said. "With that foundation, we believe we have a good chance to move further and evolve with new programs."